FG Syndrome 4: Disease Characteristics Research Report

Scope and critical curation note. FG syndrome 4 (FGS4) is an exceptionally sparsely documented historical FG-syndrome subtype. Current disease databases map it to MONDO:0010318 and associate it with CASK. However, most modern clinical and mechanistic evidence concerns the broader spectrum of CASK-related disorders, not cohorts explicitly diagnosed as FGS4. Accordingly, this report labels evidence as either direct FGS4 evidence or broader CASK-spectrum evidence; frequencies from the latter should not be entered as FGS4-specific frequencies without qualification. Open Targets identifies CASK as the sole associated target, with an association score of 0.80 and predominantly genetic support. (OpenTargets Search: FG syndrome 4)

Table: This table condenses high-yield knowledge-base facts for FG syndrome 4, clearly separating direct FG syndrome 4 evidence from broader CASK-related disorder evidence. It is useful for curation because the disease-specific literature is sparse and much current understanding is inferred from the larger CASK clinical and mechanistic spectrum.

1. Disease information

Definition

FGS4 is a rare, Mendelian, X-linked syndromic neurodevelopmental disorder historically mapped to Xp11.4–p11.3 and now linked to pathogenic variation in CASK, encoding calcium/calmodulin-dependent serine protein kinase. The modern molecular interpretation places FGS4 within the broader CASK-related neurodevelopmental spectrum, which includes X-linked intellectual disability, congenital nystagmus, epilepsy, and microcephaly with pontine and cerebellar hypoplasia (MICPCH). (OpenTargets Search: FG syndrome 4, mori2023diverseclinicalphenotypes pages 1-2)

It must not be conflated with classic FG syndrome/FG syndrome 1, which is MED12-related. Historical FG-syndrome classification was phenotype based and genetically heterogeneous; consequently, older FGS labels do not always map cleanly to current molecular diagnoses.

Identifiers and synonyms

• MONDO: MONDO:0010318.
• Causal gene association: CASK, Ensembl ENSG00000147044, chromosome Xp11.4. (OpenTargets Search: FG syndrome 4)
• Common names: FG syndrome 4; FGS4; FG syndrome type 4; CASK-related FG syndrome.
• Broader—but not strictly synonymous—terms: CASK-related disorder; CASK-related intellectual disability; X-linked intellectual disability with or without nystagmus; MICPCH.
• OMIM/Orphanet/MeSH/ICD-10/ICD-11: No independently verified FGS4-specific entries or codes were recovered in the retrieved evidence. Generic intellectual-disability, congenital-malformation, microcephaly, epilepsy, or pontocerebellar-hypoplasia codes may be used clinically, but they are not specific identifiers for FGS4.

The evidence summarized here is aggregated disease-level literature and database evidence, not individual EHR data. Some primary studies report individual patients or small cohorts.

2. Etiology

Causal factors and genetic risk

The primary cause is a germline pathogenic CASK variant. Reported CASK disease alleles across the broader spectrum include nonsense, frameshift, splice-site, missense, intragenic deletion/duplication, and larger Xp11.4 copy-number variants. Loss-of-function alleles generally reduce or eliminate functional protein; missense alleles may be hypomorphic or selectively disrupt particular molecular interactions. (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)

In a 2017 study of 41 patients selected for intellectual disability and MICPCH, 32 had CASK abnormalities—23 point variants and nine copy-number variants. The paper reports a 90.2% overall molecular identification rate, including non-CASK candidate diagnoses, rather than a 90.2% CASK rate. Parental testing showed that all assessed variants except one were de novo. (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 2-3)

Sex and X-chromosome constitution strongly influence severity. Hemizygous males have all cells exposed to the variant and severe null alleles may be perinatal lethal. Heterozygous females are mosaics through X-chromosome inactivation and often survive with variable disease. Somatic mosaicism can attenuate disease in males. (mukherjee2022thenonlinearpath pages 3-5, mori2023diverseclinicalphenotypes pages 5-7)

Environmental, lifestyle, infectious, and protective factors

No reproducible environmental toxin, infection, diet, lifestyle exposure, or occupational factor is known to cause or materially modify FGS4. No validated protective CASK allele, modifier gene, protective exposure, or gene–environment interaction was identified. Family history is relevant only through inheritance or parental germline/somatic mosaicism. These negative findings are consistent with a highly penetrant Mendelian developmental disorder, but formal gene–environment studies are lacking.

3. Phenotypes

Direct FGS4 frequency data are unavailable. The following estimates derive from aggregated CASK-related disorder literature and should be curated with that qualifier.

• Intellectual disability/global developmental delay: 96.1% of males and 93.5% of females in the 2023 review. Severity ranges from mild to profound, but severe impairment predominates in MICPCH cohorts. Suggested HPO: Intellectual disability, Global developmental delay, Delayed speech and language development. (mori2023diverseclinicalphenotypes pages 5-7)
• Microcephaly/MICPCH: 76.0% of males and 87.7% of females in the same review. Head growth may be normal or mildly reduced at birth and become progressively abnormal postnatally; prenatal onset is reported in some patients. Suggested HPO: Microcephaly, Progressive microcephaly, Pontocerebellar hypoplasia, Cerebellar hypoplasia, Pontine hypoplasia. (mori2023diverseclinicalphenotypes pages 5-7, mori2023diverseclinicalphenotypes pages 8-9)
• Epilepsy: 54.1% of males versus 36.1% of females, a reported sex difference of p=0.0198. Onset and seizure type are variable; severe males may have early refractory epilepsy. Suggested HPO: Seizure, Epileptic encephalopathy, with seizure-subtype terms assigned case by case. (mukherjee2022thenonlinearpath pages 3-5, mori2023diverseclinicalphenotypes pages 5-7)
• Motor impairment: hypotonia, dystonia, impaired coordination, delayed or absent walking, and sometimes later spasticity. In the 41-person MICPCH cohort, only 6 walked and 3 spoke, illustrating severe functional morbidity in an ascertainment-enriched cohort. Suggested HPO: Muscular hypotonia, Dystonia, Motor delay, Gait abnormality. (hayashi2017comprehensiveinvestigationof pages 2-3)
• Ophthalmologic/oculomotor disease: congenital nystagmus, optic atrophy or optic-nerve hypoplasia, glaucoma, megalocornea, and cerebral visual impairment are reported. Nystagmus has incomplete penetrance and has been associated mechanistically with C-terminal CASK–FRMD7 interactions. Suggested HPO: Congenital nystagmus, Optic atrophy, Optic nerve hypoplasia, Glaucoma, Megalocornea. (mukherjee2022thenonlinearpath pages 3-5)
• Hearing impairment: sensorineural hearing loss is recurrent. Suggested HPO: Sensorineural hearing impairment. (hayashi2017comprehensiveinvestigationof pages 2-3, martin2025theneurodevelopmentalspectrum pages 1-2)
• Growth and musculoskeletal findings: growth retardation, scoliosis, and occasionally contractures or FG-like congenital anomalies. Suggested HPO: Growth delay, Scoliosis.
• Behavioral/neuropsychiatric phenotype: autistic traits or autism-spectrum diagnoses and sleep difficulties occur in the broader CASK spectrum. Quantitative FGS4-specific data are unavailable. Suggested HPO: Autistic behavior, Sleep disturbance. (mori2023diverseclinicalphenotypes pages 1-2, martin2025theneurodevelopmentalspectrum pages 1-2)
• Facial dysmorphism: generally mild and variable in CASK cohorts; historical FG-like gestalt is insufficient for molecular diagnosis.

Symptoms are congenital or begin in infancy/childhood. The condition is lifelong. Developmental disability is generally stable, while head-growth deceleration and cerebellar degeneration can be progressive. Epilepsy may be episodic or chronic. No validated FGS4-specific EQ-5D, SF-36, PROMIS, or other quality-of-life study was found; nevertheless, impaired communication, mobility, vision, hearing, feeding, and seizure burden can substantially limit daily functioning.

4. Genetic and molecular information

Gene and variants

CASK encodes an X-linked multidomain membrane-associated guanylate kinase-family protein. Its principal domains are an N-terminal atypical CaMK domain, two L27 domains, PDZ, SH3, and guanylate-kinase-like domains. (mukherjee2022thenonlinearpath pages 5-6, mori2023diverseclinicalphenotypes pages 1-2, tibbe2021functionalanalysisof pages 1-2)

Broader CASK studies support the following genotype–phenotype tendencies:

• Nonsense and frameshift alleles usually cause loss of function and are overrepresented among affected females; severe constitutive null alleles are poorly tolerated in males.
• Missense alleles can disrupt selected binding partners and may permit survival in males. Five experimentally studied variants were p.Arg489Trp, p.Met507Ile, p.Gly521Val, p.Asn798Tyr, and p.Val849Ala. (pan2021missensemutationsin pages 4-6)
• Missense variants associated with intellectual disability and epilepsy occur throughout the protein, whereas variants associated with microcephaly/MICPCH appear more domain restricted. (mori2023diverseclinicalphenotypes pages 1-2)
• Copy-number variants can remove part or all of CASK and sometimes neighboring genes, complicating attribution.

Variants are principally germline, although somatic mosaic variants occur. Population allele frequencies for individual FGS4 alleles were not recovered; fully penetrant severe variants are expected to be absent or extremely rare in population databases. No founder allele, anticipation, or established modifier gene is known. Female expression is influenced by X-inactivation, but no validated disease-specific methylation episignature was identified.

HGNC ID, ClinVar accessions, exact HGVS sequence for the reported FGS4 splice variant, and allele frequencies should be added only after direct ClinVar/HGNC transcript verification. They were not available in the retrieved full-text evidence and should not be inferred.

5. Environmental information

No causal environmental exposure, lifestyle factor, or infectious agent applies. Smoking, alcohol, diet, exercise, pollution, radiation, and occupational exposure have not been shown to determine disease occurrence. Maternal exposures could independently affect neurodevelopment but are not recognized causes of FGS4. CTD-like chemical–gene associations should not be promoted to disease-risk factors without human evidence.

6. Mechanism and pathophysiology

Upstream-to-downstream causal model

1. Pathogenic CASK variation causes haploinsufficiency, complete loss, or selective impairment of a functional domain.
2. Protein interaction and localization defects disturb CASK scaffolding at presynaptic and postsynaptic sites and in the nucleus/cytoplasm. Important partners include neurexin, liprin-α, Mint1, Veli/Lin7, SAP97, syndecan, SynCAM, TBR1, CINAP, FRMD7, and CNTNAP2. (mukherjee2022thenonlinearpath pages 8-9, mukherjee2022thenonlinearpath pages 6-8, tibbe2021functionalanalysisof pages 1-2)
3. Synaptic and transcriptional consequences include impaired neurexin binding and neurexin-induced CASK oligomerization, altered active-zone organization, NMDA/AMPA receptor trafficking, and altered TBR1-associated regulation of RELN and GRIN2B/NR2B. (mukherjee2022thenonlinearpath pages 5-6, pan2021missensemutationsin pages 4-6, pan2021missensemutationsin pages 9-11)
4. Network/cellular consequences include altered excitatory–inhibitory balance, impaired postnatal brain growth, and vulnerability of cerebellar granule cells. Heterozygous mouse proteomics found more than 500 differentially expressed proteins, including 99 mitochondrial proteins, supporting additional cytoskeletal, translational/chaperone, and metabolic components. (mukherjee2022thenonlinearpath pages 8-9)
5. Tissue-level effects include disproportionate hindbrain and cerebellar injury, optic-nerve hypoplasia, microcephaly, and—in severe males—brainstem dysfunction affecting respiration and swallowing. These produce developmental disability, ataxia/motor impairment, epilepsy, nystagmus, and sensory deficits. (mukherjee2022thenonlinearpath pages 3-5, mukherjee2022thenonlinearpath pages 8-9)

Important expert interpretation

A simple “loss of synaptic CASK function causes maldevelopment” model is inadequate. Cask-null mice can show largely normal initial brain lamination and synaptic ultrastructure, while heterozygous animals develop postnatal abnormalities. Cell-specific deletion from Purkinje cells, retinal ganglion cells, or granule-cell precursors does not independently reproduce degeneration. This supports non-cell-autonomous, tissue-level pathogenesis and later neurodegeneration rather than a pure neuronal migration defect. (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 5-6)

The 2022 review’s central caution is that CASK molecular functions and clinical pathology have a “highly complex relationship”; mechanistic annotations should therefore separate demonstrated interactions from proven disease-causal pathways. (mukherjee2022thenonlinearpath pages 6-8)

Ontology suggestions

• GO biological process: synapse organization; regulation of synaptic vesicle exocytosis; receptor localization to synapse; regulation of transcription by RNA polymerase II; postnatal brain development; regulation of neuron death; regulation of mitochondrial metabolism.
• GO molecular function: protein-domain-specific binding; scaffold protein binding; protein serine/threonine kinase activity; neurexin binding.
• GO cellular component: presynaptic active zone; postsynaptic density; neuronal nucleus; cytosol; plasma membrane.
• Cell Ontology labels: neuron; cerebellar granule cell; Purkinje cell; retinal ganglion cell; excitatory neuron; inhibitory neuron. Exact CL identifiers should be ontology-validated before ingestion.

No validated FGS4-specific single-cell, spatial-transcriptomic, lipidomic, or metabolomic signature was found. Human induced cortical excitatory-neuron models exist in the broader CASK field, but no clinical omics biomarker is established.

7. Anatomical structures affected

The central nervous system is primary, especially:

• cerebellum, particularly the granule-cell layer;
• pons and brainstem;
• cerebral cortex and broader forebrain networks;
• optic nerve and visual pathways;
• auditory pathways.

Secondary systems include skeletal muscle/motor apparatus, spine, eyes, ears, and—depending on phenotype—feeding and respiratory systems. MRI may show pontocerebellar hypoplasia, with cerebellar involvement generally greater than pontine involvement. In the 2017 selected MICPCH cohort, all patients had MRI-confirmed pontocerebellar hypoplasia. (hayashi2017comprehensiveinvestigationof pages 2-3)

Suggested UBERON labels are brain, cerebral cortex, cerebellum, cerebellar granule layer, pons, brainstem, optic nerve, retina, inner ear, and spinal column. No consistent lateralization is established; findings are generally bilateral or diffuse.

8. Temporal development

Onset is congenital or early pediatric. Microcephaly may be prenatal but often becomes more conspicuous postnatally. Developmental delay, hypotonia, hearing loss, or nystagmus may be evident in infancy; seizures can begin in infancy or childhood. (hayashi2017comprehensiveinvestigationof pages 2-3, mori2023diverseclinicalphenotypes pages 8-9)

The course is chronic and lifelong. Head growth deceleration and cerebellar injury may progress, whereas many congenital structural abnormalities remain stable. Experimental post-developmental deletion causes granule-layer atrophy beginning around two months in mice, supporting a continuing requirement for CASK and a degenerative component. (mukherjee2022thenonlinearpath pages 6-8)

No accepted FGS4 staging system, remission pattern, or sharply defined intervention window exists. Early childhood is nonetheless a practical critical period for hearing/vision correction, seizure control, communication support, nutrition, and habilitative therapy.

9. Inheritance and population

Inheritance is X-linked. Hemizygous males are often more severely affected by loss-of-function alleles, while heterozygous females show variable expressivity because of cellular mosaicism from X-inactivation. In the 2023 aggregation, intellectual-disability frequencies were similar by sex, but epilepsy was significantly more common in males. (mori2023diverseclinicalphenotypes pages 5-7)

Many cases are de novo. Recurrence risk is usually low after a proven de novo event but is not zero because parental germline or low-level somatic mosaicism may be missed. In inherited families, a heterozygous mother may transmit the allele to 50% of pregnancies; outcome differs by fetal sex, variant effect, and X-inactivation. Female penetrance and severity are variable rather than predictably complete. Anticipation and consanguinity are not characteristic. (hayashi2017comprehensiveinvestigationof pages 2-3)

No reliable FGS4 prevalence, incidence, carrier frequency, geographic concentration, founder effect, ethnic enrichment, or population sex ratio is available. Referral cohorts are not suitable for population estimation.

10. Diagnostics

Recommended approach

1. Clinical assessment: developmental history, three-generation pedigree, growth and serial head circumference, neurologic examination, dysmorphology, vision/hearing, feeding, and musculoskeletal examination.
2. Brain MRI: assess pons, cerebellar hemispheres/vermis, cortex, white matter, ventricles, and optic structures.
3. EEG for seizures or regression; audiology/ABR and formal ophthalmology regardless of obvious symptoms.
4. Genetic testing: trio exome or genome sequencing is efficient because of phenotypic and locus heterogeneity. Analysis must include CASK single-nucleotide and indel variants and copy-number calling.
5. If phenotype strongly indicates CASK disease, use CASK sequencing plus deletion/duplication analysis. Chromosomal microarray is useful for Xp11.4 deletions/duplications but misses most sequence variants.
6. Confirm variants orthogonally when needed and test parents, including mosaic-sensitive testing where recurrence counseling depends on it.

Karyotyping and FISH have limited resolution and are appropriate mainly for a suspected large rearrangement. Mitochondrial DNA and repeat-expansion testing are not first-line. RNA sequencing can clarify a suspected splice variant or VUS but is not a routine validated diagnostic biomarker. No enzyme assay, blood metabolite, biopsy feature, liquid biopsy, or disease-specific biochemical marker is diagnostic.

Differential diagnosis

• MED12-related FG syndrome 1 and other historical FG syndromes;
• other pontocerebellar hypoplasias, including TSEN54-related disease;
• ITPR1-, RELN-, DYNC1H1-, and DCTN1-related disorders;
• other causes of syndromic X-linked intellectual disability, congenital nystagmus, microcephaly, epilepsy, or cerebellar hypoplasia. The 2017 study also identified or considered HDAC2, MARCKS, and HS3ST5 among non-CASK candidates, illustrating MICPCH heterogeneity. (hayashi2017comprehensiveinvestigationof pages 1-2)

No standardized FGS4 clinical diagnostic criteria were found; molecular confirmation is preferred. There is no population or newborn screening program. Cascade testing is appropriate after identifying a familial variant.

11. Outcome and prognosis

FGS4-specific survival curves, mortality rates, and life-expectancy estimates do not exist. Prognosis is highly variable and depends on variant class, sex, mosaicism, brainstem involvement, epilepsy, feeding/respiratory complications, and degree of developmental impairment.

Severe hemizygous null alleles may cause fetal or neonatal death or profound encephalopathy. Brainstem thinning can impair respiratory and swallowing reflexes, increasing risk of central respiratory failure, aspiration, airway infection, and pneumonia. An autopsied male with a p.Arg27Ter allele had a brain approximately 60% of expected weight and an extremely hypoplastic hindbrain. (mukherjee2022thenonlinearpath pages 3-5)

Surviving females and males with hypomorphic or mosaic variants may live into adulthood but commonly require lifelong support. Morbidity includes limited speech and mobility, epilepsy, visual/hearing impairment, scoliosis, feeding difficulties, and dependence in activities of daily living. No validated prognostic biomarker or prediction model exists.

12. Treatment and real-world implementation

There is no approved disease-modifying, gene, RNA, cell, or targeted therapy for FGS4/CASK-related disease. Treatment is individualized and supportive:

• antiseizure medication selected by seizure type and EEG;
• early physical, occupational, speech/language, feeding, and augmentative-communication therapy;
• hearing aids or cochlear evaluation as indicated;
• ophthalmologic treatment and visual-access interventions;
• nutritional and swallowing assessment, aspiration prevention, and gastrostomy when clinically required;
• orthopedic surveillance and treatment of scoliosis/contractures;
• management of sleep, constipation, respiratory problems, and behavioral distress;
• palliative/supportive planning in severe brainstem disease;
• clinical genetics and reproductive counseling.

Suggested NCIt intervention labels include Anticonvulsant Therapy, Physical Therapy, Occupational Therapy, Speech Therapy, Hearing Aid, Gastrostomy, and Genetic Counseling; exact NCIt codes should be terminology-validated before database loading.

No response rates, comparative treatment trials, CASK-specific pharmacogenomic recommendations, or treatment algorithm supported by controlled evidence were found. A search identified no FGS4/CASK-specific interventional trial. Simons Searchlight, NCT01238250, is a recruiting observational genotype-first registry relevant to rare neurodevelopmental disorders; it does not test therapeutic efficacy.

13. Prevention

Primary prevention by lifestyle modification, vaccination, environmental remediation, or medication is not applicable. Secondary and tertiary prevention consist of:

• early molecular diagnosis;
• seizure recognition and treatment;
• hearing and vision screening;
• feeding/aspiration, respiratory, and scoliosis surveillance;
• early developmental intervention.

After identifying a familial pathogenic variant, reproductive options include prenatal diagnosis and preimplantation genetic testing. Counseling must discuss variable female expression, potentially severe male disease, and residual recurrence risk from parental mosaicism. Population carrier screening and newborn screening are not established.

14. Other species and natural disease

No naturally occurring veterinary disease that is a validated homolog of human FGS4 was identified. CASK is evolutionarily conserved across vertebrates and invertebrates, but experimental ortholog disruption should not be described as naturally occurring FG syndrome. There is no infectious transmission, zoonotic potential, or cross-species contagion.

Relevant experimental taxa include:

• Mus musculus—NCBI Taxonomy 10090;
• Drosophila melanogaster—7227;
• Caenorhabditis elegans—6239.

Exact orthologous NCBI Gene IDs and any OMIA/VBO entries require dedicated database validation.

15. Model organisms and advanced models

Mouse

Constitutive Cask-null mice die within hours of birth, exhibit central respiratory failure, increased thalamic neuronal death, and cleft palate with approximately 80% penetrance. Initial brain lamination and synaptic ultrastructure are comparatively preserved, highlighting limitations of equating early structure with later disease. (mukherjee2022thenonlinearpath pages 5-6, mukherjee2022thenonlinearpath pages 3-5)

Cask+/− female mice express approximately 50% of normal CASK and reproduce major human features: postnatal microcephaly, cerebellar and optic-nerve hypoplasia, scoliosis, impaired coordination, and occasional seizures. They are useful for studying female mosaic disease but show milder behavioral and electrophysiologic phenotypes than many severely affected humans. (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 5-6)

Conditional and cell-specific deletions demonstrate that loss from Purkinje cells or retinal ganglion cells alone is insufficient to cause their death, whereas post-developmental broad deletion eventually causes cerebellar granule-cell degeneration and ataxia. These models support a non-cell-autonomous mechanism and continuing postnatal requirement for CASK. (mukherjee2022thenonlinearpath pages 6-8)

Invertebrates

CASK-null C. elegans show vulval abnormalities through the LET-23/EGF pathway but little neuronal phenotype. Drosophila CASK loss reduces locomotion without major neuromuscular-junction, motor-neuron, or premotor-neuropil abnormalities. These models reveal conserved functions but incompletely recapitulate human hindbrain disease. (mukherjee2022thenonlinearpath pages 3-5)

Cellular and structural models

Co-immunoprecipitation, bimolecular fluorescence complementation, molecular modeling, and patient-variant expression studies show that disease-associated variants can disrupt SAP97, TBR1/CINAP, and neurexin interactions. One study concluded that cooperative PDZ–SH3–GK activity is required for neurexin binding and oligomerization. (pan2021missensemutationsin pages 4-6, pan2021missensemutationsin pages 9-11)

Human fetal brain expresses at least seven CASK transcript variants, four not then represented as known GenBank variants; alternative splicing changes partner affinity, particularly SAP97 binding. This makes transcript choice an important consideration for functional variant assays. (tibbe2021functionalanalysisof pages 1-2)

Recent developments, 2023–2024

The most informative 2023 synthesis quantified sex-stratified manifestations and emphasized domain–phenotype relationships: intellectual disability affected approximately 94–96%, microcephaly/MICPCH 76–88%, and epilepsy 36% of females versus 54% of males in aggregated CASK reports. Its abstract states that CASK disorders are characterized by “MICPCH, epilepsy, congenital nystagmus, and neurodevelopmental disorders.” Published August 2023; DOI: https://doi.org/10.3390/genes14081656. (mori2023diverseclinicalphenotypes pages 1-2, mori2023diverseclinicalphenotypes pages 5-7)

A 2024 study, published online in April, used conditional mouse deletion and human variants to show that adult Cask loss can produce progressive cerebellar degeneration and that alternatively spliced vertebrate-specific exons may create region-dependent structural and functional plasticity. DOI: https://doi.org/10.1136/jmg-2023-109747. This advances mechanism and variant interpretation, but it is not yet a therapeutic breakthrough.

Evidence limitations and curation recommendations

1. Preserve FGS4 as the MONDO entity but attach a strong note that modern evidence is largely CASK-spectrum evidence.
2. Do not assign MICPCH cohort frequencies directly to FGS4 without an evidence qualifier.
3. Record variant-level assertions only after transcript-specific ClinVar/HGVS verification.
4. Mark prevalence, incidence, life expectancy, validated biomarkers, environmental risks/protectors, disease-specific clinical criteria, and controlled treatment outcomes as unknown/not available, rather than zero.
5. Treat CASK–neurexin, CASK–TBR1/GRIN2B, receptor trafficking, mitochondrial/metabolic stress, and non-cell-autonomous degeneration as complementary hypotheses with different evidence levels—not as one fully proven linear pathway.

Key publications

• Mori T, Zhou M, Tabuchi K. Diverse Clinical Phenotypes of CASK-Related Disorders and Multiple Functional Domains of CASK Protein. Genes. Published August 2023. DOI: https://doi.org/10.3390/genes14081656. (mori2023diverseclinicalphenotypes pages 1-2)
• Hayashi S, et al. Comprehensive investigation of CASK mutations and other genetic etiologies in 41 patients with intellectual disability and MICPCH. PLOS ONE. Published August 2017. DOI: https://doi.org/10.1371/journal.pone.0181791. (hayashi2017comprehensiveinvestigationof pages 1-2, hayashi2017comprehensiveinvestigationof pages 2-3)
• Pan YE, et al. Missense mutations in CASK…interfere with neurexin binding and neurexin-induced oligomerization. Journal of Neurochemistry. Published May 2021. DOI: https://doi.org/10.1111/jnc.15215. (pan2021missensemutationsin pages 4-6)
• Tibbe D, et al. Functional analysis of CASK transcript variants expressed in human brain. PLOS ONE. Published June 2021. DOI: https://doi.org/10.1371/journal.pone.0253223. (tibbe2021functionalanalysisof pages 1-2)
• Mukherjee K, LaConte LEW, Srivastava S. The Non-Linear Path from Gene Dysfunction to Genetic Disease: Lessons from the MICPCH Mouse Model. Cells. Published March 2022. DOI: https://doi.org/10.3390/cells11071131. (mukherjee2022thenonlinearpath pages 6-8, mukherjee2022thenonlinearpath pages 8-9)
• Patel PA, et al. Genetic evidence for splicing-dependent structural and functional plasticity in CASK protein. Journal of Medical Genetics. Published April 2024. DOI: https://doi.org/10.1136/jmg-2023-109747.

References

1. (OpenTargets Search: FG syndrome 4): Open Targets Query (FG syndrome 4, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (mori2023diverseclinicalphenotypes pages 1-2): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.

3. (hayashi2017comprehensiveinvestigationof pages 1-2): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.

4. (tibbe2021functionalanalysisof pages 1-2): Debora Tibbe, Yingzhou Edward Pan, Carsten Reißner, Frederike L. Harms, and Hans-Jürgen Kreienkamp. Functional analysis of cask transcript variants expressed in human brain. PLoS ONE, 16:e0253223, Jun 2021. URL: https://doi.org/10.1371/journal.pone.0253223, doi:10.1371/journal.pone.0253223. This article has 16 citations and is from a peer-reviewed journal.

5. (mukherjee2022thenonlinearpath pages 3-5): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.

6. (mori2023diverseclinicalphenotypes pages 5-7): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.

7. (hayashi2017comprehensiveinvestigationof pages 2-3): Shin Hayashi, Daniela Tiaki Uehara, Kousuke Tanimoto, Seiji Mizuno, Yasutsugu Chinen, Shinobu Fukumura, Jun-ichi Takanashi, Hitoshi Osaka, Nobuhiko Okamoto, and Johji Inazawa. Comprehensive investigation of cask mutations and other genetic etiologies in 41 patients with intellectual disability and microcephaly with pontine and cerebellar hypoplasia (micpch). PLOS ONE, 12:e0181791, Aug 2017. URL: https://doi.org/10.1371/journal.pone.0181791, doi:10.1371/journal.pone.0181791. This article has 81 citations and is from a peer-reviewed journal.

8. (mori2023diverseclinicalphenotypes pages 8-9): Takuma Mori, Mengyun Zhou, and Katsuhiko Tabuchi. Diverse clinical phenotypes of cask-related disorders and multiple functional domains of cask protein. Genes, 14:1656, Aug 2023. URL: https://doi.org/10.3390/genes14081656, doi:10.3390/genes14081656. This article has 17 citations.

9. (martin2025theneurodevelopmentalspectrum pages 1-2): Jessica Martin, Alkistis Mavrogalou-Foti, Josefine Eck, Laura Hattersley, and Kate Baker. The neurodevelopmental spectrum of cask-related disorder. Journal of Neurodevelopmental Disorders, Oct 2025. URL: https://doi.org/10.1186/s11689-025-09643-3, doi:10.1186/s11689-025-09643-3. This article has 6 citations and is from a peer-reviewed journal.

10. (mukherjee2022thenonlinearpath pages 8-9): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.

11. (mukherjee2022thenonlinearpath pages 6-8): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.

12. (pan2021missensemutationsin pages 4-6): Yingzhou Edward Pan, Debora Tibbe, Frederike Leonie Harms, Carsten Reißner, Kerstin Becker, Bri Dingmann, Ghayda Mirzaa, Anja A. Kattentidt‐Mouravieva, Moneef Shoukier, Shagun Aggarwal, Markus Missler, Kerstin Kutsche, and Hans‐Jürgen Kreienkamp. Missense mutations in cask, coding for the calcium‐/calmodulin‐dependent serine protein kinase, interfere with neurexin binding and neurexin‐induced oligomerization. Journal of Neurochemistry, 157:1331-1350, May 2021. URL: https://doi.org/10.1111/jnc.15215, doi:10.1111/jnc.15215. This article has 25 citations and is from a domain leading peer-reviewed journal.

13. (pan2021missensemutationsin pages 9-11): Yingzhou Edward Pan, Debora Tibbe, Frederike Leonie Harms, Carsten Reißner, Kerstin Becker, Bri Dingmann, Ghayda Mirzaa, Anja A. Kattentidt‐Mouravieva, Moneef Shoukier, Shagun Aggarwal, Markus Missler, Kerstin Kutsche, and Hans‐Jürgen Kreienkamp. Missense mutations in cask, coding for the calcium‐/calmodulin‐dependent serine protein kinase, interfere with neurexin binding and neurexin‐induced oligomerization. Journal of Neurochemistry, 157:1331-1350, May 2021. URL: https://doi.org/10.1111/jnc.15215, doi:10.1111/jnc.15215. This article has 25 citations and is from a domain leading peer-reviewed journal.

14. (mukherjee2022thenonlinearpath pages 5-6): Konark Mukherjee, Leslie E. W. LaConte, and Sarika Srivastava. The non-linear path from gene dysfunction to genetic disease: lessons from the micpch mouse model. Cells, 11:1131, Mar 2022. URL: https://doi.org/10.3390/cells11071131, doi:10.3390/cells11071131. This article has 7 citations.

Artifacts

• Edison artifact artifact-00